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An increasing number of patients requiring coronary artery 
bypass grafting continue to receive aspirin and other plak- 
let-inhibiting drugs at the time of surgery, in part because 
some patients reyuirer u gent operation for unstable angina or 
failed aI Igioplasty procedures. operative administration 
of aspirin, which is continued during the postoperative 
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course, has resulted in improvement in early graft patency 
rates (92.5% versus 85.2%) (I). The use of aspirin perioper- 
atively and during the first year after coronary artery bypass 
grafting also significantly improved the late patency of the 
vein grafts placed to coronary arteries ~2 mm in 
(2). However, the precise complication rate as a result of Ibe 
antiplatelet properties of aspirin has not been fully 
ated. Reports (3-6) regarding perioperative blood loss 
atients on aspirin therapy are at 
ose of this study was to analyze 
large multicenter, prospective, randomized 
inhibiting drugs in prtients undergoing co 
pass grafting in order to assess the i 
preoperative administration f aspirin. We have prtviously 
reported (I) that patients in the aspirin group had signifi- 
cantly more postoperative bleeding. In this report, we spe- 
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ci8cally compare the requirement of blood and blood prod- 
ucts and bleeding as well as other periOperatiVe COmphXitiOn 
rates in patients who did and did not receive preoperative 
aspirin therapy. 
study protoed. This Department of Veterans Affairs 
CoopC~tiVC Study entitled “Antiplatelet Therapy After Cor- 
onary Artery Bypass Graft Surgery” was a centrally di- 
rected, multicenter, andomized, double-blind, placebo- 
controlled trial designed to compare graft patency when 
placebo and four antiplatelet treatments were begun before 
and continued after coronary artery bypass grafting. The 
treatment regimens evaluated included 1) aspirin (325 msl 
day), 2) aspirin (325 mg three iimes daily), 3) aspirin (325 mg) 
and dipyridamole (75 mg) given together as a combination 
three times daily, 4) sulfinpyrazone (267 mg three times/day), 
and 5) placebo. 
The research protocol and consent forms were reviewed 
and approved by a Human Rights Committee established by
the Department of Veterans Affairs Cooperative Studies 
program Coordinating Center at the Department of Veterans 
Affairs Medical Center, Hines, Illinois on March 18, 1981, as 
well as by the Human Subjects Committee of each of the 
participating medical centers. Each participant gave written, 
informed consent before ntry into the study 
Detailed information from the history, physical examina- 
tion, routine laboratory tests, rest electrocardiogram, hemo- 
dynamic variables, coronary arteriograms, operative data, 
postoperative course and late follow-up study were collected 
prospectively in a standardized fashion. A detailed escrip 
tion of the protocol has been published elsewhere (1). 
Study patients. Between June 1983 and July 1986, 3,688 
patients underwent coronary artery bypass grafting in 12 
participating Department of Veterans Affairs medical cen- 
ters (a full listing of the participants appears in reference 1). 
Of these, 2,224 patients did not qualify for inclusion in the 
study. The exclusion criteria were: a preoperative d cision 
to perform only internal mammary artery grafts; previous 
cardiac surgery; recent history (within 1 year) of docu- 
mented gastrointestinal ulcer disease; history of bleeding 
disorder; thromboembolic disease requiring treatment --?h 
anticoagulant therapy; presence ofsignificant valvular heart 
disease repturing concomitant operation; allergy to any of 
the study drugs or the contrast agent; female patient; chronic 
disease process requiring study drugs or prostaglandin inhib- 
itors; evidence of hepatic dysfunction i dicated by elevated 
prothrombin time; or inabiliry to give written consent for the 
study. In addition to these xclusion criteria, all antiplatelet 
and nonsteroidal nti-inflammatory agents were discontin- 
ued 7 days before a.dministering any study medication. 
Of 1,464 Potential participants, 772 consented to the 
study and were enrolled in the randomized trial. Emergency 
operations, cheduling problems precluding the administ~a- 
tion of study medications according to protocol, need fort 
long-term use of aspirin and other prostaglandin i~bibitors, 
previous cardiac operations and concomitant valve re 
ment procedures were the most frequent reasons for di 
ifying patients for inclusion in the study. 
After giving written, informed consent for the study, 
patients were randomized at each participating institution. 
They were stratified at each center according to the number 
of diseased coronary arteries. Coronary arteriograms were 
scored as indicating single, double or triple vessel disease on 
the basis of 250% diameter reduction in the left anterior 
descending artery, the circumflex artery or its marginal 
branches, or both, and the right coronary plus posterior 
descending coronary artery. A ~50% stenosis of the left 
main coronary artery was counted as obstruction of two 
vessels. Stratification was done to ensure that a comparable 
number of patients with single, double and triple vessel 
disease were included in each treatment group at the indi- 
vidual institutions. 
Treatment regimens. The treatment regimens consisted 
of aspirin (325 mg once a day), aspirin (325 mg three times a 
day), combination ofaspirin (325 mg) and dipyridamole (75 
mg) three times a day, sulfinpyrazone (267 mg three times a 
day) and placebo. The therapy was started 48 h before 
operation, except when aspirin was one of the active treat- 
ment medications. Patients in all the aspirin groups received 
one 325 mg dose of aspirin 12 h preoperatively. The first 
postoperative dose of medication was administered 6 h after 
surgery through anasogastric tube, which was then clamped 
for 1.5 h. Therapy was continued by nasogastric tube until 
regular oral doses could be substituted. Details of drug 
management have been previously published (I). 
Operation. The decision for surgery was made by the 
cardiology-cardiac surgical team at the participating institu- 
tions, according to acceptable clinical indications. The sur- 
gical procedure w.as performed by either the attending 
cardiac surgeon or the surgical resident under the direct 
supervision ofau attending surgeon, according to the usual 
protocol for each study institution. At the beginning of the 
study, surgeons were encouraged touse single vein grafts 
with only one distal anastomotic site whenever possible. The 
details of ti\e operative procedure, such as mode of myocar- 
dial preservation, cardioplegic solutions, anastomotic tech- 
nique, suture material, postoperative care and indications 
for reoperation for control of postoperative bleeding, were 
left to the discretion of the operating surgeon, but were 
recorded on a standardized data form. The total duration of 
surgery, duration of cardiopulmonary b pass, interval be- 
tween completion ofcardiopulmonary b pass and skin clo- 
sure, volume of blood and blood products (platelets, fresh 
frozen plasma, cryoprecipitate) administered perioperatively 
and volume of chest tube drainage for each patient were 
recorded on the surgical data form. 
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Aspirin Grolpp Nonaspirin Group 
Qariable tn = 471) (0 = 301) 
Mean + SD 
Age (yrl 59.0 SC 8.0 58.0 t 7.0 
Canadim fJnc!iond dass (B IO IV 3.2 + 0.9 3.2 2 0.9 
Wematocrit (%I 43.0 + 4.2 42.9 2 4.0 
Nemog!obin (g) 14.7 2 2.0 14.5 2 1.3 
White blood count (lo? 7.7 2 2.0 7.7 + 2.0 
Platelets ( IQ31 270 -t 79 268 2 70 
SBP (mm Mg) 123 i 17 122 +_ 17 
DBP {mm Hg) 75 2 lil 76 ? 10 
Wean rate (beats/min) 70% 11 70 2 II 
Median Median 
GiZYii~~Xjr) 40 40 p 
Serum cholesterol (mgrdi) 222 221 
Serum triglyceride (mg/dl) I89 186 
Serum HDE (mg/dPI 34 34 
Angina 96% 9X% 
Hypertension 47% 49% 
Previous Ml 58% 57% 
*p values were not significant for any of the baseline variables. DBP = 
diastolic blood pressure; WDL = high density lipoprotein: MI = myocardial 
infarction: SBP = systolic blood pressure. 
~~ySi§. ata are presented in t 
tables as simple percent and fre~Me~cy distrib 
tinuous variables are expressed as mean Values + s 
median values. Corn arability of treatment groups was 
tested by using the ch square statistic on discrete variables 
and Student’s f test on continuous variables. Cata for 
various olperative durations, chest tube drainage and re- 
placement ofblood and blood Qroducts inthe QerioQ~~tive 
period were not normally distributed and were analyzed 
test. 
se of this report 
was to evaluate the implications ofthe preoperative admin- 
istration of aspirin in patients undergoing coronary artery 
bypass urgery, the totd study group was divided into two 
groups. 
Table 2. 35 h Chest Tube Drainage byTreatment Group 
Mean + SD Mediam F 
Treatment Group (ml) (ml) Value’ 
Placebo 920 2 534 805 
Sulfinpyrazone 949 ? 591 775 0.71(00 
Aspirin (325 mgldayi 1,239 + 1039 965 0.0190 
Aspirin + dipyridamole 1,263 2 897 loo0 Q.aOOI 
As:)irin (325 mg 3 times a daj) 1,393 c 915 1174 O.oool 
- 
*Computed from Wilcoxon rank-sum tests comparing placebo rherapy 
versus the treatment of interest. 
Bleeding Sire Aspirin Group Nonaspirin Group 
iffuse bleeding 85 2 
Surgical bleed* 12 2 
Cardiac tamponade 4 1 
Total 31 5 
*Bleeding from anastomotic site. vein graft or an identifiable source. 
een the two gi-OUQS. 
Chest tube drainage for various treat- 
ong all patients and was not due t 
(6.6%) compared with the l~onaspirin groug (1.7%). 
se generalized bleeding was tht common fmdintg at 
reoperation, and the site of bleeding did ~,oi differ betwczn 
Comparison of Total Operative Duration, 
Cardiopulmonary Bypass Duration and Interval Between 
Completion of Cardioppulmonary Bypass and Wound ~~OSKe 
Aspirin Group Nonaspirin Group p 
(mean 2 SD) (mean 2 SD) Value 
Total operative duration (min) 241 2 85 236 + 74 0.251 
Total CPB duration (min) 98 z! 38 IO3 2 43 O.ljO 
Interval between completion 75 2 49 67 f 34 0.035 
of CPB and wound closure 
(mini _ . . 
CPB = cardiopulmonary bypass. 
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Table 5. Volume of Blood and Blood Products Administered 
During Perioperative Period 
Aspirin Group Nonaspirin Group p 
(mean t SD) (mean 2 SD) Value 
RBC (ml) I.167 + 1,110 8612689 O.OOti~ 
Platelet (units) 4.5 f 7.8 2.3 + 6.4 O&lQl 
Cryoprecipitate (units) 0.50 f 2.5 0.05 + 0.7 0.0004 
FFP (ml) 888 f 1,060 651 2 771 0.0088 
Whole blood (ml) 413 k 833 337 t 673 0.4447 
FFP = fresh frozen plasma; RBC = red blood ceils. 
the two groups (Table 3). There were CC: differences between 
the two groups for either total operative duration or duration 
of cardiopulmonary bypass, but the interval between cessa- 
tion of cardiopulmonary bypass and completion of the pro- 
cedure was significantly longer in patients receiving aspirin 
(Table 4). This may indicate that the patients receiving 
preoperative aspirin required more time to achieve adequate 
hemostasis in the operating room af!er they were weaned 
from cardiopulmonary bypass. 
ucts (Tables 5and 6). 
Patients in the aspirin group received more packed red blood 
cells (p = O.OOOl), platelets (p= O.Ol?Ol), cryoprecipitate (p = 
0.0004) and fresh frozen plasma (p = 0.0088) than did the 
patients in the nonaspirin group (Table 5). Seven percent of 
the patients in the aspirin group and 6.5% in the nonaspirin 
group did not receive any blood or blood product perioper- 
atively. There was no difference in the number of patients 
receiving either ed brood cells or whole blood, but more 
patients in the aspirin group received replacement therapy 
with fresh frozen plasma, platelets and cryoprecipitate (Ta- 
ble 6). 
Operative mortality and ccamplic&~. The overall in- 
hospital mortality :‘dte and 30 day operative mortality rate 
was 2.3%. It was 2.5% for patients in the aspirin group and 
2.0% for the nonaspirin group (p = 0.619). The postoperative 
bleeding was neither a primary nor a contributing cause of 
death in any of these patients. A detailed analysis of post- 
operative complications (excluding reoperation for control 
of bleeding) failed to show any difference between the two 
@QUPS (Table 7). Twenty-one patients (4.5%) in the aspirin 
Table 6. Percent of Patients Receiving Blood 
Replacement Therapy 
Therapy Aspirin Group Nonaspirin Group p Value 
Blood or blood products 93. I 93.5 NS 
Red blood cells 88.9 86.9 NS 
Whole blood 29.7 27.8 NS 
FFP 65.5 57.7 0.003 
platelets 39.7 21.6 0.001 
Cryoprecipitate 6.6 0.4 O.oM)l 
FFP = fresh frozen plasma. 
Table 7. Postoperative Complications* 
Aspirin Group Nonaspirin 
(n = 4ii) Group (n = 301) 
Complication No. Y- NC % 
Reoperation for bleeding 33 6.6 5 1.7 
Myocardiai infarction 29 6.2 14 4.7 
Respiratory failure 12 2.5 5 1.7 
Pneumonia 16 3.4 6 2.0 
Wound infection 10 2.i 5 I.7 
Renal failure 3 0.6 2 0.7 
Pulmonary embo!ism 3 0.6 3 1.0 
Atriai arrhythmia 79 16.8 50 16.6 
Ventricular arrhythmia 44 9.3 28 9.3 
- 
*p values were significant only for reoperation to control bleeding (p = 
O.M)2L 
group experienced bleeding complications that were not 
related to the operation, an incidence that was similar to that 
in the patients in the nonas irin group (Table 8). 
Effkcts of ~~~~~~tiv~ ris. The present study demon- 
strates that the preoper administration f aspirin in 
patients undergoing coronary artery bypass grafting in- 
creases perioperative blood loss, the requirement for red 
blood cells and other blood products and the rate 
ation for the control of ~ost~~c~~t~ve b eed~~8~ 
preoperative aspirin does not affect he operative mortality 
rate or the incidence of other postoperative complications. 
These results support e findings of otbes investigators 
(3-8) who also found increased perioperative blood loss with 
comparable doses of preoperative aspirin. Others (9,10) have 
suggested that a lower dose of preoperative aspirin (1 mglkg) 
is not associated with increased operative blood loss, even 
though it profoundly inhibits platelet aggregation a d throm- 
bo synthesis. 
perative aspirin and postoperative bl e 
jor causes of postoperative bleeding after coronary artery 
Table 8. Incidence of Other Bleeding Complications* (not related 
to surgical wound) 
Aspirin Group Nonaspirin Group 
Complication (n = 471) (n = 3011 
Epistaxis 2 I 
Hematuria 5 5 
Melena 7 3 
Hemarthrosis 2 2 
Hematemesis 1 0 
Hematoma 3 2 
Other I 2 
Total 21 (4.5%) 15 (5.0%) 
*p values were not sigilicanl for any of these bleeding complications. 
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venible of the active site o 
atelet f~~stio~ as 
ue to take this dru 
co~t~~~~ it duria:, the post 
e patiertts ~~derg~9ing 
coronary a~gio~lasty may restore an emergency operation 
127,28). These patients usually receive aspirin before the 
(29) have demonstrated the 
late patency of the dilated 
se reasons, many physkia 
followed by combined therapy of aspirir, and d~~y~~darno~e 
postoperatively is very effective in improving early vein graft 
patency without producing postoperative bleeding complica- 
tions. Our study, however, found no additional benefit when 
cy after corolraary rtery 
rative screeniaag tests 
or salicy~ate d term~~ 
tra~§f~§~o~ of shed mediastinal blood duricg the postopera- 
tive period. The amount of perioperative bleeding, tke use of 
bkzd atd Aood products as well as the re¶u~reme~t of 
reoperatio~ to colatrol postoperative bleedi 
distributed among ail of the ~art~c~~ating centers, and there 
wa3 no clustering of complication events in any one center. 
The use of blood or blood products, or both, irn 330% of 
patients appears to be high by the current standards. There 
were no guide~ine§ in the research protocol for administra- 
tion of these products. ~~~~~g the od of this trial, most of 
the centers were not utilizing II savers or autologous 
transfusion of shed ediastinal blood. The internal 
mary artery was used fre dissection of this 
vessel tends to cause incr 
basis of results of this and 
postoperative admiaistration f blood and blood products 
should be reconsidered. Use of cell saver or hemoconcen- 
trator intraoperatively and autologous transfusion of shed 
20 SETHIETAL. JACC Vol. 15. No. 1 
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mediastinal b ood postoperatively will reduce the require- 
ment of blood, In the event of excessive postoperative 
bleeding, determination f prothrombin time, partial throm- 
boplastin time, platelet count and bleeding time should be 
obtained. Desmopressin acetate has been shown (21) to 
correct the prolonged bleeding time and reduce postopera- 
tive bleeding after coronary artery bypass grafting. Occa- 
sionally, platelet infusion may be necessary tocorrect pro- 
longed bleeding time, and this therapy should be considered 
in patients with excessive bleeding whose platelet count is 
<100,0Wmm3 postoperatively. Fresh frozen plasma and 
cryoprecipitate do not correct bleeding due to aspirin inges- 
tion and should be administered only to correct appropriate 
coagulation factors. The judicious use of blood and blood 
products will decrease their attendant risks of transfusion 
reaction, hepatitis, histocompatibility sensitization and ac- 
quired immunodeficiency syndrome (AIDS). 
Cliieal implications. The data from this study should be 
helpful to surgeons in identifying patients who may be at a 
higher isk for developing significant postoperative bleeding 
and should provide guidance for appropriate plans for man- 
agement. The results of this study also prompted the initia- 
tion of a sequel trial to compare the benefits and risks of 
preoperative rsus early postoperative (6 h) initiation of 
aspirin therapy. Until the results of the new trial are known, 
the dat!a from this study should be taken into ‘I .Isideration 
for risk assessment i  patients undergoing cu. Silary artery 
bypass grafting. 
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